Pediatrix Medical Group, Inc. filings document the public-company disclosures of a Florida physician-services operator focused on obstetrics, maternal-fetal medicine, neonatology and pediatric subspecialty care. Recent Form 8-K reports furnish operating results, including net revenue, earnings measures, same-unit revenue drivers, reimbursement factors, patient volume trends and hospital-based practice activity.
Proxy and governance filings cover director elections, shareholder voting results, executive compensation, pay-versus-performance data and the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan. Other material-event reports address board appointments, Regulation FD disclosures and common-stock repurchase authorizations.
Pediatrix Medical Group, Inc. provided an update on second quarter 2026 business trends, noting that its payor mix remained stable and unchanged relative to recent historical trends and internal expectations, despite reports of adverse utilization and reimbursement shifts elsewhere in the healthcare sector.
The company stated it has not experienced unfavorable payor mix shifts or material changes in other net revenue-related trends. Pediatrix reaffirmed its full year 2026 outlook for Adjusted EBITDA in a range of $280 million to $300 million, supported by a reconciliation from net income. Pediatrix plans to discuss results for the quarter ended June 30, 2026 on an investor conference call and webcast on August 4, 2026 at 9:00 a.m. ET.
Pediatrix Medical Group Inc is reported to have a significant institutional holder, as Dimensional Fund Advisors LP may be deemed the beneficial owner of 4,220,311 shares of its common stock, representing 5.1% of the outstanding class.
Dimensional reports sole voting power over 4,117,448 shares and sole dispositive power over 4,220,311 shares, with no shared voting or dispositive power. The shares are owned by investment funds that Dimensional advises, and Dimensional disclaims beneficial ownership of these securities other than for Section 13(d) reporting purposes.
Haddock David reported acquisition or exercise transactions in this Form 4 filing.
Pediatrix Medical Group EVP David Haddock received new equity awards. On 2026-06-22, he was granted 20,036 shares of common stock at no cost as restricted shares under the company’s incentive compensation plan.
He also received 51,000 Performance Share Units, each tied to one common share. These PSUs vest after three years only if both service and stock performance conditions are met. Shares are earned in one-third increments based on Pediatrix’s stock trading at 115%, 125% and 135% of $22.66 for at least 20 consecutive trading days before the third anniversary of the grant date.
Pediatrix Medical Group, Inc. executive David Haddock, who serves as EVP, General Counsel and Corporate Secretary, submitted an initial Form 3 insider ownership report. The filing lists no transactions or derivative positions, functioning as a baseline disclosure of his status as a reporting officer.
Pediatrix Medical Group EVP and General Counsel Mary Ann E. Moore reported bona fide gifts of 36,814 shares of common stock. The transactions on June 9, 2026 moved 18,407 shares to a family trust and 18,407 shares from her direct holdings. After these transfers, she holds 78,059 shares directly and 111,831 shares indirectly through the trust, with beneficial interest limited to her pecuniary stake.
Pediatrix Medical Group EVP, CFO and Treasurer Kasandra H. Rossi received 31,800 restricted shares of common stock as an annual equity award under the company’s incentive compensation plan. The award vests 25% on June 1, 2027, 25% on June 1, 2028, and 50% on June 1, 2029. In connection with vesting of prior awards, 3,701 restricted shares were withheld to cover taxes. After these transactions, Rossi directly holds 101,399 common shares.
Pediatrix Medical Group Chief Executive Officer Mark S. Ordan reported a series of equity compensation adjustments and tax-related share withholdings. He received 127,198 restricted shares on June 1, 2026 at no cost under the company’s Second Amended and Restated 2008 Incentive Compensation Plan, tied to an annual equity award. A portion of these restricted shares is scheduled to vest 25% on June 1, 2027, 25% on June 1, 2028 and 50% on June 1, 2029, subject to the plan’s terms.
The filing also shows 19,119 restricted shares of common stock disposed of on June 1, 2026 at a price of $21.54 per share, representing shares withheld to cover taxes upon vesting. In addition, 97,174 restricted shares were granted on June 2, 2026 and 97,174 shares were returned to the issuer the same day. This pair of transactions reflects a revision to a 194,347-share annual equity award originally granted on June 1, 2025 so it complies with the plan’s annual award limitations, while preserving the intended vesting schedule. After these transactions, Ordan directly holds 410,884 shares of Pediatrix Medical Group common stock.
Pediatrix Medical Group EVP and Chief Investment & Strategy Officer Don Gregory Neeb reported routine equity compensation activity. He received a grant of 63,888 restricted shares of common stock under the company’s Second Amended and Restated 2008 Incentive Compensation Plan as part of an annual equity award.
According to the vesting schedule, 25% of these restricted shares will vest on June 1, 2027, 25% on June 1, 2028, and 50% on June 1, 2029, subject to the plan’s terms. In a related tax-withholding disposition, 8,003 restricted shares were withheld to cover taxes upon vesting of shares. After these entries, Neeb directly holds 137,231 Pediatrix common shares.
Pediatrix Medical Group EVP Mary Ann E. Moore reported a routine share withholding for taxes. On the vesting of restricted stock, 11,944 common shares were withheld at $21.54 per share to cover tax obligations, classified as a tax-withholding disposition.
After this event, she directly holds 96,466 common shares. A separate trust, for which she and her spouse serve as trustees, holds 93,424 common shares indirectly; she disclaims beneficial interest in those shares beyond her pecuniary interest.
Pediatrix Medical Group director-linked trust sells shares
A trust associated with director Shirley A. Weis sold 36,028 shares of Pediatrix Medical Group common stock in an open-market transaction at a weighted average price of $23.75 per share, with individual trade prices ranging from $23.55 to $23.85.
The shares were held by The Weis Family Trust, for which Shirley A. Weis and her husband serve as trustees and members of her immediate family are beneficiaries. Following the sale, the trust reported no remaining Pediatrix shares, while Weis directly holds 18,623 shares.